These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66 related articles for article (PubMed ID: 29552327)
41. The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials. Sonbol MB; Mountjoy LJ; Firwana B; Liu AJ; Almader-Douglas D; Mody K; Hubbard J; Borad M; Ahn DH; Murad MH; Bekaii-Saab T JAMA Oncol; 2020 Mar; 6(3):e194489. PubMed ID: 31855256 [TBL] [Abstract][Full Text] [Related]
42. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Jang HJ; Kim BJ; Kim JH; Kim HS Oncotarget; 2017 Sep; 8(42):73009-73016. PubMed ID: 29069844 [TBL] [Abstract][Full Text] [Related]
43. Cancer Statistics, 2017. Siegel RL; Miller KD; Jemal A CA Cancer J Clin; 2017 Jan; 67(1):7-30. PubMed ID: 28055103 [TBL] [Abstract][Full Text] [Related]
44. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Luo HY; Li YH; Wang W; Wang ZQ; Yuan X; Ma D; Wang FH; Zhang DS; Lin DR; Lin YC; Jia J; Hu XH; Peng JW; Xu RH Ann Oncol; 2016 Jun; 27(6):1074-1081. PubMed ID: 26940686 [TBL] [Abstract][Full Text] [Related]
45. Cancer statistics in China, 2015. Chen W; Zheng R; Baade PD; Zhang S; Zeng H; Bray F; Jemal A; Yu XQ; He J CA Cancer J Clin; 2016; 66(2):115-32. PubMed ID: 26808342 [TBL] [Abstract][Full Text] [Related]
46. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Hagman H; Frödin JE; Berglund Å; Sundberg J; Vestermark LW; Albertsson M; Fernebro E; Johnsson A Ann Oncol; 2016 Jan; 27(1):140-7. PubMed ID: 26483047 [TBL] [Abstract][Full Text] [Related]
47. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518 [TBL] [Abstract][Full Text] [Related]
48. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971 [TBL] [Abstract][Full Text] [Related]
49. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517 [TBL] [Abstract][Full Text] [Related]
50. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Koeberle D; Betticher DC; von Moos R; Dietrich D; Brauchli P; Baertschi D; Matter K; Winterhalder R; Borner M; Anchisi S; Moosmann P; Kollar A; Saletti P; Roth A; Frueh M; Kueng M; Popescu RA; Schacher S; Hess V; Herrmann R Ann Oncol; 2015 Apr; 26(4):709-714. PubMed ID: 25605741 [TBL] [Abstract][Full Text] [Related]
51. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Díaz-Rubio E; Gómez-España A; Massutí B; Sastre J; Abad A; Valladares M; Rivera F; Safont MJ; Martínez de Prado P; Gallén M; González E; Marcuello E; Benavides M; Fernández-Martos C; Losa F; Escudero P; Arrivi A; Cervantes A; Dueñas R; López-Ladrón A; Lacasta A; Llanos M; Tabernero JM; Antón A; Aranda E; Oncologist; 2012; 17(1):15-25. PubMed ID: 22234633 [TBL] [Abstract][Full Text] [Related]
52. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Waddell T; Gollins S; Soe W; Valle J; Allen J; Bentley D; Morris J; Lloyd A; Swindell R; Taylor MB; Saunders MP Cancer Chemother Pharmacol; 2011 May; 67(5):1111-7. PubMed ID: 20676676 [TBL] [Abstract][Full Text] [Related]
53. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Moher D; Liberati A; Tetzlaff J; Altman DG; Int J Surg; 2010; 8(5):336-41. PubMed ID: 20171303 [No Abstract] [Full Text] [Related]
54. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. Chibaudel B; Maindrault-Goebel F; Lledo G; Mineur L; André T; Bennamoun M; Mabro M; Artru P; Carola E; Flesch M; Dupuis O; Colin P; Larsen AK; Afchain P; Tournigand C; Louvet C; de Gramont A J Clin Oncol; 2009 Dec; 27(34):5727-33. PubMed ID: 19786657 [TBL] [Abstract][Full Text] [Related]
56. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. Tournigand C; Cervantes A; Figer A; Lledo G; Flesch M; Buyse M; Mineur L; Carola E; Etienne PL; Rivera F; Chirivella I; Perez-Staub N; Louvet C; André T; Tabah-Fisch I; de Gramont A J Clin Oncol; 2006 Jan; 24(3):394-400. PubMed ID: 16421419 [TBL] [Abstract][Full Text] [Related]
57. Who will benefit more from maintenance therapy of metastatic colorectal cancer? Zhou M; Fu L; Zhang J Oncotarget; 2018 Feb; 9(15):12479-12486. PubMed ID: 29552327 [TBL] [Abstract][Full Text] [Related]
58. Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis. Zhou M; Yu P; Qu J; Chen Y; Zhou Y; Fu L; Zhang J Cell Physiol Biochem; 2016; 40(1-2):361-369. PubMed ID: 27866194 [TBL] [Abstract][Full Text] [Related]
59. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322 [TBL] [Abstract][Full Text] [Related]